Dr. Reddys net profit – Artifex.News https://artifex.news Stay Connected. Stay Informed. Wed, 22 Jul 2026 14:16:00 +0000 en-US hourly 1 https://wordpress.org/?v=7.1.4 https://artifex.news/wp-content/uploads/2026/05/cropped-cropped-app-logo-32x32.png Dr. Reddys net profit – Artifex.News https://artifex.news 32 32 Dr. Reddy’s Q1 net plunges 69% to ₹435.6 cr on lower revenue https://artifex.news/article71253745-ece/ Wed, 22 Jul 2026 14:16:00 +0000 https://artifex.news/article71253745-ece/ Read More “Dr. Reddy’s Q1 net plunges 69% to ₹435.6 cr on lower revenue” »

]]>

Hyderabad-based generic drugmaker Dr. Reddy’s Laboratories’ consolidated net profit slumped 69% year-on-year (YoY) to ₹.435.6 crore in the June quarter amid lower sales of cancer drug lenalidomide and nearly ₹240 crore provision necessitated by recent quality issue around weight loss drug Semaglutide.

Total revenue from operations stood at ₹8,099.8 crore (₹8,572.1 crore), showed its results prepared in accordance with Indian Accounting Standards (Ind AS).

“Our Q1FY27 performance reflected the expected transition beyond lenalidomide revenues, along with an unexpected impact related to semaglutide active pharmaceutical ingredient (API). However, our underlying base business continued to deliver healthy double digit growth across all key geographies,” co-chairman and managing director G V Prasad said.

The focus remains on improving health of the base business through disciplined execution and operational excellence, while building future pipeline of peptides, biosimilars and innovative assets to deliver long-term growth, he said.

An adverse product mix, primarily on account of reduced sales of lenalidomide (generic of Revlimid), price erosion in North America and Europe generics, the semaglutide API related provision impact besides elevated solvent costs and freight costs on account of the Middle East crisis impacted the gross margin, Dr. Reddy’s said.

The underlying base business, excluding lenalidomide, continued to deliver healthy double-digit growth across all geographies, including North America, aided by favourable currency movements.

On the provision, the drugmaker said certain batches of Semaglutide were found to be out of specification due to an issue associated with the API used in the product. “Consequently, based on its best estimate, the company has made a provision of ₹.239.7 crore towards inventory and other associated costs during the quarter ended June 30, 2026,” it said.



Source link

]]>
Dr. Reddy’s Q4 dips 86% on lower sales, multiple one offs to ₹221 crore https://artifex.news/article70973283-ece/ Wed, 13 May 2026 07:54:00 +0000 https://artifex.news/article70973283-ece/ Read More “Dr. Reddy’s Q4 dips 86% on lower sales, multiple one offs to ₹221 crore” »

]]>

On the SSA, the company said it recorded ₹453 crore as a reduction of revenue from sale of goods in its Global Generics Segment.
| Photo Credit: The Hindu

Pharma major Dr. Reddy’s Laboratories reported consolidated net profit slumped to ₹221.3 crore for the March quarter compared to ₹1,586.7 crore a year earlier on the back of lower sales and multiple one offs.

Total revenue from operations of the Hyderabad-headquartered generic drugmaker was lower at ₹7,546.4 crore (₹8,528.4 crore), according to the results prepared as per Indian Accounting Standards (Ind AS).

The company said the results include the adverse impact of a Shelf Stock Adjustment (SSA) related to lenalidomide (generic of cancer drug Revlimid) of ₹453 crore, impairment of CAR-T assets and Eftilagimod Alfa of a total of ₹227.7 crore, provisions related to VAT liability of ₹114.1 crore during the quarter.

On the SSA, the company said it recorded ₹453 crore as a reduction of revenue from sale of goods in its Global Generics Segment.

For the fiscal ended March, Dr. Reddy’s consolidated net profit declined to ₹4,157.6 crore (₹5,725.2 crore). Total revenue from operations rose to ₹33,700 crore (₹32,643.9 crore).

The company said FY26 results includes adverse impact of VAT liability provision of ₹69.5 crore and New Labour Codes of ₹117 crore.

“Our performance this year reflects the impact of lower lenalidomide sales and several one-offs. The resilience of our branded businesses and currency tailwinds helped partially mitigate this impact. We remain focused on strengthening our base business and improving margins, through cost efficiencies and portfolio optimisation,” Co-Chairman and MD G.V. Prasad said.

The company has declared a final dividend of ₹8 per equity share (face value of ₹1 each) for FY26.



Source link

]]>